Moderna, Inc.: Moderna Completes Application To U.S. Food And Drug Administration For Emergency Use Authorization Of Omicron-Targeting Bivalent Covid-19 Booster Vaccine, mRNA-1273.222
MRNA-1273.222 Targets BA.4/BA.5 Strains of Omicron VariantPending Authorization, Moderna Ready to Ship Bivalent Booster mRNA-1273.222 in SeptemberClinical Data Available for Moderna's Bivalent COVID-19
Source: finanznachrichten.de